

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM405774

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
SIGA Technologies, Inc.		11/16/2016	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Cortland Capital Market Services, LLC		
Street Address:	225 West Washington Street		
Internal Address:	21st Floor		
City:	Chicago		
State/Country:	ILLINOIS		
Postal Code:	60606		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 8			
Property Type	Number	Word Mark	
Registration Number:	3729965	SIGA	
Registration Number:	3703521	SIGA	
Registration Number:	3723743	SIGA	
Registration Number:	3719987	SIGA	
Registration Number:	3703520	HUMAN BIOARMOR	
Registration Number:	3415362	ST-246	
Registration Number:	4597614	ARESTVYR	
Registration Number:	5046109	TPOXX	
CORRESPONDENCE DATA			
Fax Number:	3128622200		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	3128622000		
Email:	rob.soneson@kirkland.com		
Correspondent Name:	Rob Soneson		
Address Line 1:	300 N LaSalle		
Address Line 2:	Kirkland & Ellis LLP		
Address Line 4:	Chicago, ILLINOIS 60654		
ATTORNEY DOCKET NUMBER:	17625-7-RFS		

CH \$215.00 3729965

NAME OF SUBMITTER:	Rob Soneson
SIGNATURE:	/rsoneson/
DATE SIGNED:	11/16/2016
Total Attachments: 8 source=Oaktree - Siga - IP Security Agreement (EXECUTED 11.16.2016)_(44330340_1)#page1.tif source=Oaktree - Siga - IP Security Agreement (EXECUTED 11.16.2016)_(44330340_1)#page2.tif source=Oaktree - Siga - IP Security Agreement (EXECUTED 11.16.2016)_(44330340_1)#page3.tif source=Oaktree - Siga - IP Security Agreement (EXECUTED 11.16.2016)_(44330340_1)#page4.tif source=Oaktree - Siga - IP Security Agreement (EXECUTED 11.16.2016)_(44330340_1)#page5.tif source=Oaktree - Siga - IP Security Agreement (EXECUTED 11.16.2016)_(44330340_1)#page6.tif source=Oaktree - Siga - IP Security Agreement (EXECUTED 11.16.2016)_(44330340_1)#page7.tif source=Oaktree - Siga - IP Security Agreement (EXECUTED 11.16.2016)_(44330340_1)#page8.tif	

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (as the same may be amended, restated, supplemented or otherwise modified from time to time, the "Agreement"), dated as of November 16, 2016, is made by SIGA Technologies, Inc., a Delaware corporation ("Grantor"), in favor of Cortland Capital Market Services, LLC as administrative and collateral agent (in such capacity, together with its successors and permitted assigns, the "Agent") for the Lenders (as defined in the Loan Agreement referred to below).

WITNESSETH:

WHEREAS, pursuant to the Loan and Security Agreement, dated as of September 2, 2016 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), among Grantor, the other loan parties party thereto from time to time, the Lenders from time to time party thereto and Agent, the Lenders have severally agreed to make the Term Loan to Grantor upon the terms and subject to the conditions set forth therein; and

WHEREAS, pursuant to the Loan Agreement, Grantor is required to execute and deliver this Agreement.

NOW, THEREFORE, in consideration of the premises and to induce the Lenders and the Agent to enter into the Loan Agreement and to induce the Lenders to make the Loans to Grantor thereunder, Grantor hereby agrees with the Agent as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Loan Agreement.

Section 2. Grant of Security Interest in Collateral. Grantor, as security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of all Obligations, hereby grants to the Agent, for the benefit of Agent and Lenders a Lien on and security interest in, all of its right, title and interest in, to and under the following property of Grantor, whether now owned or hereafter acquired, and wherever located (the "Collateral"):

(a) all Intellectual Property including, without limitation, those referred to on Schedule I hereto;

(b) all licenses providing for the grant by or to Grantor of any right under any Intellectual Property, including, without limitation, those referred to on Schedule I hereto;

(c) all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals, reversions and extensions of the foregoing;

(d) all goodwill of the Grantor connected with the use of, and symbolized by, such Intellectual Property; and

(e) all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

Notwithstanding the above, "Collateral" shall not include the Excluded Property (as defined in the Loan Agreement) and, except as provided in the Loan Agreement, is not to be construed as a present assignment of any Intellectual Property.

Section 3. Loan Agreement. The security interest granted pursuant to this Agreement is granted in conjunction with the security interest granted to the Agent pursuant to the Loan Agreement and Grantor hereby acknowledges and agrees that the rights and remedies of the Agent with respect to the security interest in the Collateral made and granted hereby are more fully set forth in the Loan Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

Section 4. Grantor Remains Liable. Grantor hereby agrees that, anything herein to the contrary notwithstanding, Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with its Intellectual Property subject to a security interest hereunder, pursuant to the terms of the Loan Agreement.

Section 5. Counterparts. This Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart. Delivery of an executed signature page of this Agreement by facsimile transmission or electronic transmission shall be as effective as delivery of a manually executed counterpart hereof.

Section 6. Governing Law. This Agreement and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,

SIGA TECHNOLOGIES, INC., as Grantor


By: Robin E. Abrams

Name: Robin E. Abrams

Title: General Counsel and Chief
Administrative Officer

ACCEPTED AND AGREED
as of the date first above written:

CORTLAND CAPITAL MARKET SERVICES LLC, as Agent

By: 
Name: Emily Ergang Pappas
Title: Associate Counsel

SCHEDULE I

Patents

Compound Series	Title/Description	Country	Application/ Patent No.	Status
Tecovirimat (ST-246, TPOXX) Family I	<i>COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES</i> Method of treatment, compounds, pharmaceutical composition, method of making	US	7,737,168	Issued
		US	8,124,643	Issued
		US	7,956,197	Issued
		US	7,687,641	Issued
		US	8,039,504	Issued
		US	8,530,509	Issued
		US	8,802,714	Issued
		US	9,045,418	Issued
Tecovirimat (ST-246, TPOXX) Family II	<i>POLYMORPHIC FORMS ST-246 AND METHODS OF PREPARATION</i> Polymorphic forms I, II, IV, VI processes for their preparation, methods of treatment, pharmaceutical compositions, and dosage unit forms	US	9,339,466	Issued
		US	14/959,180	Pending
Tecovirimat (ST-246, TPOXX) Family III	<i>ST-246 LIQUID FORMULATIONS</i> Liquid formulations comprising cyclodextrin, methods of treatment, process for making, unit dosage forms	US	9,233,097	Issued
		US	14/955,674	Pending
Tecovirimat (ST-246, TPOXX) Family IV	<i>METHODS OF PREPARING TECOVIRIMAT</i> Methods of preparation	US	14/420,728	Pending

Compound Series	Title/Description	Country	Application/ Patent No.	Status
Tecovirimat (ST-246, TPOXX) Family V	<i>AMORPHOUS TECOVIRIMAT PREPARATION</i> Amorphous form	US	14/903,083	Pending
Tecovirimat (ST-246, TPOXX) Family VI	<i>REHYDRATION OF MICRONIZATION TECOVIRIMAT MONOHYDRATE</i> Rehydration/Micronization	US	15/027,557	Pending
Tecovirimat (ST-246, TPOXX) Family VII	<i>ST-246 (TECOVIRIMAT MONOHYDRATE) SUSPENSION FORMULATIONS</i> Suspension formulations	US Provisional	62/295,710	Pending
ST-981/ Dengue	ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION Pharmaceutical compositions and methods of treating dengue infection	US	8,518,960	Issued
		US	9,353,061	Issued
		US	15/148,241	Pending
ST-610/ Dengue	SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION Pharmaceutical compositions and methods of treating dengue infection	US	9,029,376	Issued
		US	14/673,102	Pending
ST-148/ Dengue	THIENOPYRIDINE DERIVATIVES FOR THE	US	9,301,949	Issued
		US	15/017,748	Pending

Compound Series	Title/Description	Country	Application/ Patent No.	Status
	TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS Pharmaceutical compositions and methods of treating dengue infection, intermediates and compounds	US	13/708,224	Pending
ST-659/ Dengue	TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTION Pharmaceutical compositions , methods of treating dengue infection and compounds	US	8,993,604	Issued
		US	14/616,187	Pending
ST-669/ Broad-spectrum	INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND CATEGORY A AND B VIRAL PATHOGENS Pharmaceutical compositions for use in treating a viral or bacterial infection and compounds, and stabilized aqueous nanosuspensions and methods of a broad spectrum anti-virals	US	9,233,087	Issued
		US	14/955,697	Pending
Ebola	SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF EBOLA VIRUS Pharmaceutical composition and a method of treatment	US Provisional	62/316,779	Pending

Trademarks

Trademark	Country	Class	Application/ Registration No.	Status	Registration Date
SIGA	US	5	3729965	Registered	12/22/2009
	US	42	3703521	Registered	10/27/2009
SIGA+Design	US	5	3723743	Registered	12/8/2009
	US	42	3719987	Registered	12/1/2009
Human BioArmor	US	42	3703520	Registered	10/27/2009
ST-246	US	5	3415362	Registered	4/22/2008
ARESTVYR	US	5	4,597,614	Registered	9/2/2014
TPOXX	US	5	5046109	Registered	9/20/16